Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150013/S033

PD-L1 IHC 22C3 pharmDx

Agilent Technologies, Inc. · Decision date Feb 10, 2026

FDA DECISIONP150013/S033

What did the FDA approve?

FDA records P150013/S033 as a supplement to PMA P150013, with the supplement type “Panel Track”. The recorded decision is approval, dated Feb 10, 2026.

FDA approval order statement

Approval for the PD-L1 IHC 22C3 pharmDx for expanding the indications to include use as an aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) for treatment with KEYTRUDA (pembrolizumab).
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Pathology
Decision date
Feb 10, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P150013/S033
Regulatory pathway
PMA supplement
Product code
PLS
Decision code
APPR
Decision date
Feb 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry assay, antibody, programmed death-ligand 1.

Product code
PLS
FDA device class
3

For the original device and its historical approval scope, see PMA P150013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150013 · Original PMA

    PD-L1 IHC 22C3 PHARMDX

  2. P150013/S028 · Related supplement

    PD-L1 IHC 22C3 pharmDx (Dako Omnis)

  3. P150013/S033 received

    Application receipt date recorded by FDA.

  4. P150013/S033 · FDA decision

    Panel Track

Timeline entries are records held by MedtechLedger for P150013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150013

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA approvalOct 2, 2015FDA
Agilent Technologies, Inc.PMA supplementAug 4, 2025FDA
Agilent Technologies, Inc.PMA supplementFeb 11, 2026FDA
Agilent Technologies, Inc.PMA supplementMar 19, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Other records with product code PLS

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA supplementJul 1, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5301 Stevens Creek Blvd., Santa Clara, CA, 95051

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records